In the aftermath of CATIE: How should administrators value atypical antipsychotic medications?

Administration and Policy in Mental Health and Mental Health Services Research

Volumn 33, Issue 5, 2006, Pages 541-543

  Luchins, Daniel J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Atypical antipsychotics; Pharmacoeconomics; Schizoprenia

Indexed keywords

ANTIPARKINSON AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; ZIPRASIDONE; CLOZAPINE; RISPERIDONE;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HUMAN; METABOLIC DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RESOURCE ALLOCATION; SCHIZOPHRENIA; SIDE EFFECT; TARDIVE DYSKINESIA; WEIGHT GAIN; COST CONTROL; DRUG WITHDRAWAL; HOSPITALIZATION; MENTAL DISEASE; NEGATIVE SYNDROME; PATIENT COMPLIANCE; RISK ASSESSMENT; TREATMENT FAILURE;

ADMINISTRATIVE PERSONNEL; ANTIPSYCHOTIC AGENTS; ECONOMICS, PHARMACEUTICAL; HUMANS; RANDOMIZED CONTROLLED TRIALS; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 33746877158     PISSN: 0894587X     EISSN: 15733289     Source Type: Journal    
DOI: 10.1007/s10488-006-0049-z     Document Type: Article

References (8)

1. Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry, 60, 553-564.
2. Essock S. M., Frisman L. K., Covell N. H., & Hargreaves, W. A. (2000). Cost effectiveness of Clozapine compared to conventional antipsychotic medication for patients in state hospitals. Archives of General Psychiatry, 57, 987-994.
3. Freedman, R. (2005).The choice of antipsychotic drugs for schizophrenia. New England Journal of Medicine, 353, 1286-1288.
4. Kane, J., Honingfeld, G., Singer, J., & Meltzer, H. (1989). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
5. Leucht, S., Wahlbeck, K., Hamann, J., & Kissling, W. (2003). New generation antipsychotics versus low potency conventional antipsychotics: A systematic review and meta-analysis. Lancet, 361, 1581-1589.
6. Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B., Severe, J., & Hsiao, J. K. (2005). Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209-1223.
7. Luchins, D. J., Chiriac, I., Hanrahan, P., Goldman, M., Fabian, R., & Tolley, G. (2005). Allocating funds for medications and psychosocial interventions: How consumers would divide the pie. Psychiatric Services, 56, 799-801.
8. Rosenheck, R. A. (2005). Effectiveness versus efficacy of second-generation antipsychotics: Haloperidol without anticholinergics as a comparator. Psychiatric Services, 56, 85-92.